Table 2 Signs and symptoms evaluated during the clinical trial
Months 0-4 | Months 4-6 | ||||
|---|---|---|---|---|---|
Placebo N (%) | Buccalin N (%) | Placebo N (%) | Buccalin N (%) | ||
Cough intensity | Weak | 29 (49.2) | 42 (57.5) | 4 (50.0) | 2 (40.0) |
Moderate | 26 (44.1) | 30 (41.1) | 2 (25.0) | 2 (40.0) | |
Severe | 4 (6.8) | 1 (1.4) | 2 (25.0) | 1 (20.0) | |
Total | 59 | 73 | 8 | 5 | |
Dyspnoea | Weak | 9 (52.9) | 19 (70.4) | 1 (33.3) | 1 (33.3) |
Moderate | 6 (35.3) | 8 (29.6) | 0 (0.0) | 1 (33.3) | |
Severe | 2 (11.8) | 0 (0.0) | 2 (66.7) | 1 (33.3) | |
Total | 17 | 27 | 3 | 3 | |
Pain | Weak | 16 (69.6) | 26 (63.4) | 4 (80.0) | 4 (80.0) |
Moderate | 7 (30.4) | 15 (36.6) | 0 (0.0) | 1 (20.0) | |
Severe | 0 (0.0) | 0 (0.0) | 1 (20.0) | 0 (0.0) | |
Total | 23 | 41 | 5 | 5 | |
Fever | Weak | 8 (30.8) | 11 (32.4) | 1 (25.0) | 1 (50.0) |
Moderate | 17 (65.4) | 23 (67.6) | 2 (50.0) | 1 (50.0) | |
Severe | 1 (3.8) | 0 (0.0) | 1 (25.0) | 0 (0.0) | |
Total | 26 | 34 | 4 | 2 | |